Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Recruiting 2Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Cancer Metastatic 1

Interventions

Carboplatin 108Cisplatin 98Paclitaxel 79pembrolizumab 70Gemcitabine 60Pemetrexed 49Cyclophosphamide 48Dexamethasone 47Docetaxel 46durvalumab 44Capecitabine 44Radiotherapy 42Doxorubicin 40Lenalidomide 38Specimen Handling 37Nivolumab 37Oxaliplatin 35Rituximab 34Magnetic Resonance Spectroscopy 33Fluorouracil 33Etoposide 32Bevacizumab 32Vincristine 30atezolizumab 29Radiation 28Leucovorin 28Bortezomib 26Prednisone 23Letrozole 23Fulvestrant 23

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Active not recruiting × dalpiciclib × Clear all
NCT06612814 2024-09-25

PARP Inhibitor With CDK4/ 6 Inhibitor and Endocrine Therapy in HR+/ HER2-Advanced Breast Cancer

Fudan University

Phase 3 Active not recruiting
307 enrolled
Breast

Breast Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡